Rezultati - Plummer, Ruth
- Showing 1 - 20 results of 45
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors od Plummer, Ruth, Stephens, Peter, Aissat-Daudigny, Louiza, Cambois, Anne, Moachon, Gilbert, Brown, Peter D., Campone, Mario
Izdano 2014Text -
6
-
7
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours od Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S
Izdano 2020Text -
8
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours:... od Cranston, Amy, Stocken, Deborah D., Stamp, Elaine, Roblin, David, Hamlin, Julia, Langtry, James, Plummer, Ruth, Ashworth, Alan, Burn, John, Rajan, Neil
Izdano 2017Text -
9
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study od Brown, Jennifer, Plummer, Ruth, Bauer, Todd M., Anthony, Stephen, Sarantopoulos, John, De Vos, Filip, White, Mike, Schupp, Marco, Ou, Ying, Vaishampayan, Ulka
Izdano 2017Text -
10
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours od Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.
Izdano 2021Text -
11
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours od Middleton, Mark R., Dean, Emma, Evans, Thomas R. J., Shapiro, Geoffrey I., Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth
Izdano 2021Text -
12
-
13
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors od Plummer, Ruth, Madi, Ayman, Jeffels, Melinda, Richly, Heike, Nokay, Bahar, Rubin, Stephen, Ball, Howard A., Weller, Steve, Botbyl, Jeffrey, Gibson, Diana M., Scheulen, Max E.
Izdano 2012Text -
14
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965 od McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Izdano 2020Text -
15
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965 od McNeillis, Rosie, Greystoke, Alastair, Walton, Jon, Bacon, Chris, Keun, Hector, Siskos, Alexandros, Petrides, George, Leech, Nicola, Jenkinson, Fiona, Bowron, Ann, Halford, Sarah, Plummer, Ruth
Izdano 2020Text -
16
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study proto... od Menne, Tobias, Slade, Daniel, Savage, Joshua, Johnson, Sarah, Irving, Julie, Kearns, Pamela, Plummer, Ruth, Shenton, Geoff, Veal, Gareth J, Vormoor, Britta, Vormoor, Josef, Billingham, Lucinda
Izdano 2022Text -
17
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine od Twelves, Chris, Anthoney, Alan, Savulsky, Claudio I., Guo, Matthew, Reyderman, Larisa, Cresti, Nicola, Semiglazov, Vladimir, Timcheva, Constanta, Zubairi, Ishtiaq, Morrison, Rosemary, Plummer, Ruth, Evans, T. R. Jeffry
Izdano 2019Text -
18
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours od Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Izdano 2017Text -
19
-
20
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor od Plummer, Ruth, Dua, Divyanshu, Cresti, Nicola, Drew, Yvette, Stephens, Peter, Foegh, Marie, Knudsen, Steen, Sachdev, Pallavi, Mistry, Bipin M., Dixit, Vaishali, McGonigle, Sharon, Hall, Nancy, Matijevic, Mark, McGrath, Shannon, Sarker, Debashis
Izdano 2020Text